MY186444A - Gene therapy to improve vision - Google Patents

Gene therapy to improve vision

Info

Publication number
MY186444A
MY186444A MYPI2017001247A MYPI2017001247A MY186444A MY 186444 A MY186444 A MY 186444A MY PI2017001247 A MYPI2017001247 A MY PI2017001247A MY PI2017001247 A MYPI2017001247 A MY PI2017001247A MY 186444 A MY186444 A MY 186444A
Authority
MY
Malaysia
Prior art keywords
light
photoreceptor
gene therapy
improve vision
responds
Prior art date
Application number
MYPI2017001247A
Other languages
English (en)
Inventor
Matteo Rizzi
Robin Ali
Alexander Smith
Koji Nishiguchi
Original Assignee
Ucl Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Business Ltd filed Critical Ucl Business Ltd
Publication of MY186444A publication Critical patent/MY186444A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MYPI2017001247A 2015-02-23 2016-02-19 Gene therapy to improve vision MY186444A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201503008A GB201503008D0 (en) 2015-02-23 2015-02-23 Treatment
PCT/GB2016/050419 WO2016135457A1 (en) 2015-02-23 2016-02-19 Gene therapy to improve vision

Publications (1)

Publication Number Publication Date
MY186444A true MY186444A (en) 2021-07-22

Family

ID=52822045

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2017001247A MY186444A (en) 2015-02-23 2016-02-19 Gene therapy to improve vision

Country Status (29)

Country Link
US (3) US20180030477A1 (enExample)
EP (1) EP3261679B1 (enExample)
JP (1) JP6771474B2 (enExample)
KR (1) KR102272466B1 (enExample)
CN (1) CN107530449A (enExample)
AU (2) AU2016225277B2 (enExample)
CA (1) CA2977464C (enExample)
CY (1) CY1126098T1 (enExample)
DK (1) DK3261679T3 (enExample)
EA (1) EA201791900A1 (enExample)
ES (1) ES2947308T3 (enExample)
FI (1) FI3261679T3 (enExample)
GB (1) GB201503008D0 (enExample)
HK (1) HK1248594A1 (enExample)
HR (1) HRP20230775T1 (enExample)
HU (1) HUE062319T2 (enExample)
IL (1) IL254066B (enExample)
LT (1) LT3261679T (enExample)
MX (1) MX2017010772A (enExample)
MY (1) MY186444A (enExample)
PH (1) PH12017501525B1 (enExample)
PL (1) PL3261679T3 (enExample)
PT (1) PT3261679T (enExample)
RS (1) RS64372B1 (enExample)
SG (2) SG11201706822XA (enExample)
SI (1) SI3261679T1 (enExample)
SM (1) SMT202300200T1 (enExample)
WO (1) WO2016135457A1 (enExample)
ZA (1) ZA201706440B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3516046B1 (en) * 2016-09-22 2022-07-13 Sorbonne Université Optogenetically transformed photoreceptor precursor cells for the use in the treatment of retinal degenerative diseases
JP2024524600A (ja) * 2021-07-06 2024-07-05 インスティテュート オブ モレキュラー アンド クリニカル オフサルモロジー バーゼル 桿体光受容体における遺伝子の特異的発現のためのプロモーター

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2442670A1 (en) * 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
EP3437473A1 (en) * 2006-05-04 2019-02-06 Wayne State University Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids
PT2271369E (pt) * 2008-04-18 2014-07-10 Novartis Forschungsstiftung Novas ferramentas terapêuticas e métodos para tratar a cegueira
US20140099284A1 (en) * 2010-10-15 2014-04-10 Eos Neuroscience, Inc Modulation neural pathways
US8957028B2 (en) * 2010-11-13 2015-02-17 Massachusetts Institute Of Technology Red-shifted opsin molecules and uses thereof
WO2012167109A2 (en) * 2011-06-03 2012-12-06 Massachusetts Eye & Ear Infirmary Rpgrip1 gene therapy for leber congenital amaurosis
WO2013124477A1 (en) * 2012-02-24 2013-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of retinal degenerative diseases
US20170182191A1 (en) * 2014-07-29 2017-06-29 Circuit Therapeutics, Inc. System and method for optogenetic therapy

Also Published As

Publication number Publication date
PH12017501525B1 (en) 2023-08-30
AU2016225277A1 (en) 2017-10-12
PT3261679T (pt) 2023-07-04
HRP20230775T1 (hr) 2023-10-27
EP3261679A1 (en) 2018-01-03
GB201503008D0 (en) 2015-04-08
FI3261679T3 (fi) 2023-06-28
WO2016135457A1 (en) 2016-09-01
HUE062319T2 (hu) 2023-10-28
ZA201706440B (en) 2021-06-30
EA201791900A1 (ru) 2018-02-28
DK3261679T3 (da) 2023-06-26
CA2977464A1 (en) 2016-09-01
LT3261679T (lt) 2023-07-10
AU2022201553A1 (en) 2022-03-31
KR102272466B1 (ko) 2021-07-02
SI3261679T1 (sl) 2023-09-29
JP2018506982A (ja) 2018-03-15
MX2017010772A (es) 2018-03-01
US20250290096A1 (en) 2025-09-18
PH12017501525A1 (en) 2018-02-05
ES2947308T3 (es) 2023-08-04
US20200377907A1 (en) 2020-12-03
CN107530449A (zh) 2018-01-02
CA2977464C (en) 2022-04-05
BR112017018062A2 (pt) 2018-04-10
PL3261679T3 (pl) 2023-09-04
US20180030477A1 (en) 2018-02-01
RS64372B1 (sr) 2023-08-31
NZ735735A (en) 2021-09-24
HK1248594A1 (zh) 2018-10-19
IL254066B (en) 2021-10-31
HK1248595A1 (en) 2018-10-19
AU2022201553B2 (en) 2024-08-15
IL254066A0 (en) 2017-10-31
CY1126098T1 (el) 2023-11-15
AU2016225277B2 (en) 2021-12-09
EP3261679B1 (en) 2023-05-03
SMT202300200T1 (it) 2023-09-06
SG11201706822XA (en) 2017-09-28
KR20180012737A (ko) 2018-02-06
SG10202005923WA (en) 2020-07-29
JP6771474B2 (ja) 2020-10-21

Similar Documents

Publication Publication Date Title
MX2023007496A (es) Antifolatos poliglutamados y sus usos.
PH12018500964A1 (en) Modified friedreich ataxia genes and vectors for gene therapy
PH12018502645A1 (en) Optimized mini-dystrophin genes and expression cassettes and their use
EA201890640A1 (ru) Рекомбинантные векторы, содержащие пептид 2а
MX2020003425A (es) Tratamiento de trastornos inflamatorios.
MX2021014955A (es) Formulaciones subcutaneas de anticuerpos anti-cd38 y sus usos.
EA201891317A3 (ru) Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения
WO2016100985A3 (en) Chimeric antigen receptors and methods of use thereof
WO2015168532A3 (en) Compositions and methods for modulating pkk expression
MX2018002899A (es) Tratamiento de retinitis pigmentosa.
MX2018000395A (es) Proteinas y composiciones inmunizantes que contienen proteinas de klebsiella y metodos de uso.
IL268357A (en) Photoreceptor cells for the treatment of retinal diseases
ZA201701881B (en) Adeno-associated viral vectors for treating myocilin (myoc) glaucoma
ZA202108987B (en) 1-amino-1-cyclopropanecarboxylic acid hudrochloride formulations
MY195000A (en) Method for the treatment of neurological disease
MX2018005872A (es) Profarmacos de acido nucleico.
CY1126098T1 (el) Γονιδιακη θεραπεια για τη βελτιωση της ορασης
IL275126B (en) Methods for predicting the progression of Barrett's esophagus
PH12016501326A1 (en) (s)-3'-methyl-abscisic acid and esters thereof
ZA201901505B (en) Phenylalanine-free protein for the treatment of pku
ZA202202125B (en) Nanoemulsion of 18 beta-glycyrrhetinic acid
WO2013103792A3 (en) Method of treating cancer by administration of low levels of heat shock protein 70 (hsp70)
WO2014144815A3 (en) Vectors and methods to treat ischemia
HK40027614A (en) Enhancing agents for improved cell transfection and/or raav vector production
TH1601001388A (th) สารเพื่อลดแคแทบอลิซึมหรือกระตุ้นแอนาบอลิซึมของโปรตีน